Imperial College London

ProfessorNagyHabib

Faculty of MedicineDepartment of Surgery & Cancer

Professor of Hepatobiliary Surgery
 
 
 
//

Contact

 

+44 (0)20 3313 8574nagy.habib

 
 
//

Assistant

 

Mrs Benita White +44 (0)20 3313 2261

 
//

Location

 

BN1/17 B BlockHammersmith HospitalHammersmith Campus

//

Summary

 

Awards

  • Doctor Honoris Causa, University of Medicine and Pharmacy, Cluj-Napoca, Romania, 2011
  • Visiting Professor of Hepatic Surgery, First Affiliated Hospital of Harbin Medical University, 2010
  • Board Member International Centre of Excellence for Technical Innovation in Surgery, University of Naples, Itlay, 2017
  • Honorary Diploma, Bulgarian Surgical Society, 2014
  • Visiting Professor of Hepatobiliary Department, Tainjian Medical Univeristy Cancer Institute, 2010
  • Honorary Foreign Member, French Academy of Surgery, 2015
  • Scientific and Technological Achievement, TAKREEM, 2012
  • Named as one of top 100 surgeons in the UK, The Times newspaper, 2011
  • Gold Clinical Excellence Award, ACCEA, 2011

External Positions

Membership of Professional Bodies

Links with Other Academic Bodies

  • Development and innovation in endoscopic medical devices, Weill Cornell Medicine, 2014
  • Development and targeting of aptamers in liver diseases., Professor John Rossi, Beckman Research Institute, City of Hope, 2013
  • A FIRST-IN-HUMAN, MULTI-CENTRE, OPEN-LABEL, PHASE 1 CLINICAL STUDY WITH RNA OLIGONUCLEOTIDE DRUG MTL-CEBPA TO INVESTIGATE ITS SAFETY AND TOLERABILITY IN PATIENTS WITH ADVANCED LIVER CANCER (OUTREACH), The National Cancer Centre Singapore, 2016
  • A FIRST-IN-HUMAN, MULTI-CENTRE, OPEN-LABEL, PHASE 1 CLINICAL STUDY WITH RNA OLIGONUCLEOTIDE DRUG MTL-CEBPA TO INVESTIGATE ITS SAFETY AND TOLERABILITY IN PATIENTS WITH ADVANCED LIVER CANCER (OUTREACH), University Hospitals Birmingham NHS Foundation Trust, 2016
  • A FIRST-IN-HUMAN, MULTI-CENTRE, OPEN-LABEL, PHASE 1 CLINICAL STUDY WITH RNA OLIGONUCLEOTIDE DRUG MTL-CEBPA TO INVESTIGATE ITS SAFETY AND TOLERABILITY IN PATIENTS WITH ADVANCED LIVER CANCER (OUTREACH), University College London Hospitals NHS Foundation Trust, 2016
  • A FIRST-IN-HUMAN, MULTI-CENTRE, OPEN-LABEL, PHASE 1 CLINICAL STUDY WITH RNA OLIGONUCLEOTIDE DRUG MTL-CEBPA TO INVESTIGATE ITS SAFETY AND TOLERABILITY IN PATIENTS WITH ADVANCED LIVER CANCER (OUTREACH), National Taiwan University Hospital, 2016
  • A FIRST-IN-HUMAN, MULTI-CENTRE, OPEN-LABEL, PHASE 1 CLINICAL STUDY WITH RNA OLIGONUCLEOTIDE DRUG MTL-CEBPA TO INVESTIGATE ITS SAFETY AND TOLERABILITY IN PATIENTS WITH ADVANCED LIVER CANCER (OUTREACH), The Newcastle upon Tyne Hospitals NHS Foundation Trust
  • A FIRST-IN-HUMAN, MULTI-CENTRE, OPEN-LABEL, PHASE 1 CLINICAL STUDY WITH RNA OLIGONUCLEOTIDE DRUG MTL-CEBPA TO INVESTIGATE ITS SAFETY AND TOLERABILITY IN PATIENTS WITH ADVANCED LIVER CANCER (OUTREACH), The Clatterbridge Cancer Centre NHS Foundation Trust, 2016
  • A FIRST-IN-HUMAN, MULTI-CENTRE, OPEN-LABEL, PHASE 1 CLINICAL STUDY WITH RNA OLIGONUCLEOTIDE DRUG MTL-CEBPA TO INVESTIGATE ITS SAFETY AND TOLERABILITY IN PATIENTS WITH ADVANCED LIVER CANCER (OUTREACH), Cambridge University Hospitals NHS Trust, 2016
  • Department of Research Oncology, King’s College London, 3rd Floor, Bermondsey Wing, Guy’s Hospital, Great Maze Pond, London SE1 9RT, United Kingdom, The Beatson West of Scotland Cancer CentreCancer Research UK Clinical Trials Unit, 1053 Great Western Rd, Glasgow G12 0YN, United Kingdom, 2016
  • A First-in-Human, multi-centre, open-label, phase 1 clinical study with RNA oligonucleotide drug MTL-CEBPA to investigate its safety and tolerability in patients with advanced liver cancer (OUTREACH)., Guys & St Thomas Foundation TrustKings College University, 2016

Industrial Connections

  • OmniCyte Limited, Director
  • Apterna Limited, Director
  • EMcision Limited, Board Member, Director
  • MiNA Therapeutics Ltd, Cheif Medical Officer for clinical study:A FIRST-IN-HUMAN, MULTI-CENTRE, OPEN-LABEL, PHASE 1 CLINICAL STUDY WITH RNA OLIGONUCLEOTIDE DRUG MTL-CEBPA TO INVESTIGATE ITS SAFETY AND TOLERABILITY IN PATIENTS WITH ADVANCED LIVER CANCER (OUTREACH) Study

Commercial Spinoffs

  • OmniCyte Limited and Associated Companies, Board Member, Regenerative medicine in the field of stem cells, 2003
  • EMcision Limited

Fellowships

  • Fellow, Royal College of Surgeons of Edinburgh

Editorial Boards

  • World Journal of Gastroenterology, Editorial Board
  • Molecular Therapeutics Nucleic Acids (Open Access journal), Deputy Editor
  • Hepatoma, Deputy Chief Editor, 2012 - 2015
  • Clinical Oncology and Cancer Research, Editorial Board, 2012
  • Cancer Biology and Therapy, Editorial Board Member, 2001
  • Cancer Gene Therapy Journal, Editorial Board Member, 1999
  • Chirurgie, Editorial Board Member, 1998